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In vertebrates, unfertilized eggs are arrested at meiotic metaphase II (meta-II) by cytostatic factor (CSF), with Cdc2 activity maintained at
a constant, high level. CSF is thought to suppress cyclin B degradation through the inhibition of the anaphase-promoting complex/cyclosome
(APC/C)-Cdc20 while cyclin B synthesis continues in unfertilized eggs. Thus, it is a mystery how Cdc2 activity is kept constant during CSF
arrest. Here, we show that the APC/C–Cdc20 can mediate cyclin B degradation in CSF-arrested Xenopus eggs and extracts, in such a way
that when Cdc2 activity is elevated beyond a critical level, APC/C–Cdc20-dependent cyclin B degradation is activated and Cdc2 activity
consequently declines to the critical level. This feedback control of Cdc2 activity is shown to be required for keeping Cdc2 activity constant
during meta-II arrest. We have also shown that Mos/MAPK pathway is essential for preventing the cyclin B degradation from inactivating
Cdc2 below the critical level required to sustain meta-II arrest. Our results indicate that under CSF arrest, Mos/MAPK activity suppresses
cyclin B degradation, preventing Cdc2 activity from falling below normal meta-II levels, whereas activation of APC/C–Cdc20-mediated
cyclin B degradation at elevated levels of Cdc2 activity prevents Cdc2 activity from reaching excessively high levels.
D 2005 Elsevier Inc. All rights reserved.
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In vertebrates, mature eggs wait for fertilization with the
meiotic cycle being arrested at metaphase of meiosis II
(meta-II). The arrest at meta-II, which can last for a few
days, is caused by the action of cytostatic factor (CSF),
which was first identified in frog eggs (Masui and Markert,
1971). CSF arrest is established in meiosis II (MII) by the
Mos/MAPK cascade (Kishimoto, 2003; Masui, 2000;
Sagata, 1996) and is terminated through the activation of
calcium/calmodulin kinase II (CaMKII) induced by a
transient increase in Ca2+ concentration in the egg cyto-
plasm upon fertilization (Lorca et al., 1993; Morin et al.,
1994). In CSF-arrested eggs, metaphase is maintained
through keeping the cyclin B-Cdc2 kinase activity at a high0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.12.025
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E-mail address: kohsumi@bio.titech.ac.jp (K. Ohsumi).level, which is achieved by maintaining the levels of cyclin
B. In contrast, when eggs are released from CSF arrest by
fertilization, cyclin B is rapidly degraded to undetectable
levels, resulting in Cdc2 inactivation and hence exit from
MII. It has been postulated that cyclin B degradation is
suppressed during CSF arrest in unfertilized vertebrate eggs
to sustain a prolonged metaphase prior to fertilization
(Abrieu et al., 2001; Tunquist and Maller, 2003).
Cyclin B degradation, which is catalyzed by the 26S
proteasome, is regulated through polyubiquitination by the
anaphase-promoting complex/cyclosome (APC/C), an E3
ubiquitin ligase, and its activating factor Cdc20 (for review,
see Harper et al., 2002; Peters, 2002). The APC/C is inactive
in interphase and activated in M-phase through phosphor-
ylation (for review, see Peters, 2002). The APC/C–Cdc20 is
known to be suppressed in the metaphase arrest caused by
the spindle assembly checkpoint (for review, see Yu, 2002),
and the checkpoint proteins Bub1, Mad1 and Mad2 were
shown to be involved in CSF arrest (Tunquist et al., 2002,279 (2005) 345–355
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arrested eggs, cyclin B degradation is suppressed through
prevention of APC/C–Cdc20 (for review, see Abrieu et al.,
2001; Tunquist and Maller, 2003). On the other hand, there
is evidence that considerable amounts of cyclin B are
continuously synthesized in unfertilized eggs of the mouse
and Xenopus (Kubiak et al., 1993; Thibier et al., 1997).
Furthermore, cyclin B synthesis has been reported to
increase in the presence of Mos/MAPK activity during the
period from meiosis I (MI) to MII (Gross et al., 2000). Thus,
the suppression of cyclin B degradation and continuous
cyclin B synthesis in unfertilized eggs would be expected to
lead to ever increasing Cdc2 activity, rather than the
constant level seen during the long-lasting CSF arrest.
To address this issue, we have investigated the main-
tenance of Cdc2 activity at a constant level during meta-II
arrest, using CSF-arrested Xenopus eggs and their extracts
(CSF extracts) (Lohka and Maller, 1985; Murray et al.,
1989). Our results show that, contrary to the widely-
accepted model, the APC/C–Cdc20 can mediate cyclin B
degradation in CSF-arrested eggs and extracts, in such a
way that when Cdc2 activity is elevated beyond a critical
level, APC/C–Cdc20-dependent cyclin B degradation is
activated and Cdc2 activity consequently declines to the
critical level. This feedback control of Cdc2 activity is
shown to be required for keeping Cdc2 activity constant
during meta-II arrest. We have also shown that Mos/MAPK
pathway is critical in preventing the cyclin B degradation
from inactivating Cdc2 below the critical level required to
sustain an MII metaphase arrest.Materials and methods
Recombinant proteins
Full-length Xenopus cyclin B1 cDNA (gift from T. Hunt)
was cloned into the pTrc-His2A plasmid vector (Invitrogen)
and transformed into Escherichia coli strain BL21. Myc/
His6-tagged recombinant protein was expressed at 228C for
14 h with 1 mM IPTG and purified using His-Bind Resin
(Novagen). GST-DN85 cyclin B2 (DN cyclin B2; Iwabuchi
et al., 2000) was expressed at 258C for 4 h with 1mM IPTG
in E. coli strain BL21 and purified according to the
manufacturer’s protocol (Amersham). The kinase inactive
complex of Cdc2 and GST-DN cyclin B2 was produced as
described previously (Iwabuchi et al., 2000). The construct
for GST-Ste11DN (Gotoh et al., 1994) was kindly provided
from E. Nishida. Protein was expressed in E. coli strain
XLIBlue and purified according to the manufacturer’s
protocol (Amersham).
All the purified proteins were dialyzed against extraction
buffer (EB: 100 mM KCl, 5 mM MgCl2, 10 mM HEPES-
KOH, pH 7.5) supplemented with 1 mM DTT, concentrated
with microcon (Millipore) or vivaspin (Vivascience), frozen
in liquid nitrogen and stored at 808C.Oocytes, eggs and extracts
Fully-grown oocytes and mature eggs of Xenopus were
obtained as described (Ohsumi et al., 1994). CSF extracts of
unfertilized eggs were prepared by the method of Murray
(Murray, 1991) with modifications. Briefly, unfertilized
eggs of Xenopus were dejellied with 2.5% thioglycolic
acid–NaOH (pH 8.2), washed 5 times with EGTA-extraction
buffer (EEB: 100 mM KCl, 5 mM MgCl2, 0.1 mM CaCl2, 5
mM EGTA, 20 mM HEPES-KOH, pH 7.4) and packed into
a 1.5- or 2-ml plastic tube filled with EEB containing 50 Ag/
ml cytochalasin B. After a brief centrifugation (750 g, 10 s,
28C), excess buffer was removed, and eggs were lysed by
centrifugation at 15,000  g for 10 min at 48C. The
cytoplasmic fraction between lipid cap and sedimented yolk
was removed and centrifuged again at 15,000  g for 20
min at 48C to remove contaminating lipid. Interphase egg
extracts were prepared by adding 0.4 mM CaCl2 to CSF
extracts at 228C. Fully-grown oocytes were treated with 10
Ag/ml progesterone to induce the resumption of meiosis, and
extracts were prepared from oocytes at metaphase of
meiosis I as described (Iwabuchi et al., 2000). Egg and
oocyte extracts were kept on ice and used within 2 h of
preparation. All incubations of extracts were done at 228C.
In some experiments, oocytes matured in vitro were
injected with 14 nl of 10 mM EGTA either with or without 6
AM of undegradable Emi1 (Ohsumi et al., 2004), and then
injected with 9 nl of 3.3 AM His-cyclin B1.
Antibodies, immunodepletion and immunoblot analysis
Full-length Xenopus Cdc20 cDNA (Lorca et al., 1998)
was isolated by PCR and cloned into pGEX4T-3 plasmid
vector (Amersham). GST-Cdc20 fusion protein expressed in
E. coli strain BL21 and contained in inclusion bodies was
suspended into 6 M urea and diluted with the equal volume
of PBS, by which most GST-Cdc20 protein was precipi-
tated. Precipitated protein was then dissolved into SDS
sample buffer (SSB: 10% glycerol, 2% SDS, 5% h-
mercaptoethanol, 0.0025% bromophenol blue, 60 mM
Tris–HCl, pH6.8). After separation by SDS–PAGE, GST-
Cdc20 protein was electroeluted from the acrylamide gel,
dialysed against PBS and used to immunize rabbits. Full-
length Xenopus Mos cDNA (gift from N. Sagata) was
cloned into pGEX plasmid vector (gift from K. Tachibana).
GST-Mos fusion protein was expressed in E. coli strain
BL21, purified according to manufacturer’s protocol
(Amersham) and used to immunize rabbits. Antisera raised
against Cdc20 were pretreated with GST-beads, and Cdc20
antibodies were affinity-purified from the pretreated sera
with nitrocellulose membranes onto which GST-Cdc20
protein had been transferred. Mos antibodies were affinity-
purified from antisera with GST-Mos covalently conjugated
to CNBr-coupling gel (Amersham). Purified antibodies were
dialyzed against EB, concentrated with vivaspin (Vivas-
cience) and stored at 808C.
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extracts, purified antibodies for Xenopus Mos and human
Cdc27 (mAB AF3; Yamano et al., 98) were conjugated to
Protein G–Sepharose beads (sigma), and CSF extracts were
treated twice with 10% extract volume of each antibody-
beads. For mock-depletion, Protein G-beads conjugated
with rabbit IgG were used. For immunoblot analysis,
extracts were mixed with SSB, boiled for 2 min, run on
SDS–polyacrylamide gels and transferred to nitrocellulose
membranes. After blocking with 10% skimmed milk,
membranes were incubated with primary antibodies for 2
h at room temperature or for 12 h at 48C. Antibodies used
were anti-Xenopus Mos, anti-Xenopus cyclin B1 and cyclin
B2 (gift from J. L. Maller), anti-Cdc27 (MBL; TL-C40920)
and anti-MAPK (Upstate; 06-182). After incubation with
alkaline phosphatase-conjugated secondary antibodies,
membranes were processed for visualizing signals by the
BCIP/NBL phosphatase substrate system (KPL).
Protein synthesis measurement
For labeling proteins synthesized in egg extracts, 8.6 ACi
of 35S-methionine and cysteine (Pro mix L-[35S] in vitro cell
labeling mix: Amersham) was added to 10 Al of extracts
either with or without 100 Ag/ml CHX and incubated at
228C. After a 30-min incubation, 3 Al of extracts were mixed
with 17 Al of SSB. For precipitation with Protein G-beads
conjugated with Xenopus cyclin B1 and B2 antibodies, 7 Al
of extracts were diluted with 35 Al of cold kinase buffer (80
mM h-glycerophosphate, 20 mM EGTA, 5 mM MgCl2, 20
mM HEPES-KOH, pH 7.5) and treated with 10 Al of either
bead as described previously (Ohsumi et al., 1994) and
beads-bound proteins were eluted with SSB. After boiling
for 3 min, samples were subjected to SDS–PAGE, and the
gel was stained with Coomassie Blue (CBB) and dried onto
filter paper. 35S incorporation into proteins separated byFig. 1. Cyclin B synthesis continues in CSF extracts. (A) CSF extracts with or with
and cysteine for 30 min at 228C (Whole), and then treated with Xenopus cyclin B
bound by the antibody beads (P) were separated SDS–PAGE and autoradiographe
applied (lower). Arrowhead indicates the position of cyclin B. (B, C) The rate of
incubation by 30-min pulse labeling with 35S-methionine and cysteine. Error bar
synthesis rate in CSF extracts is compared with that in activated extracts (I-phase).
rate in CSF extracts was measured various times after incubation. The synthesisSDS–PAGE was analyzed with Bio-imaging analyzer (Fuji
Photo Film).
Histone H1 kinase activity assay
For histone H1 kinase assay, extracts were quickly frozen
in liquid nitrogen and stored at 808C. Frozen extracts were
thawed by adding 9 volumes of ice-cold kinase buffer. As for
oocytes, five oocytes were crashed in 20 Al of kinase buffer
and after a centrifugation (10,000  g, 1 min, 28C), 10 Al of
cytoplasmic fraction was collected. Ten microliters of
thawed extracts or oocyte cytoplasmic extracts was mixed
with 20 Al of reaction buffer (80 mM h-glycerophosphate,
pH 7.4, 20 mMMgCl2, 0.6 mM ATP, 30 Ag/ml leupeptin, 30
Ag/ml aprotinin) containing 0.6 ng/ml histone H1 and 1 ACi
[g-32P] ATP, and incubated for 30 min at 258C. Reactions
were stopped by the addition of SSB and boiling for 2 min.
Histone H1 was separated by SDS–PAGE and stained with
CBB and the band was excised. 32P incorporation into the gel
slice was quantified by the Cerenkov method.ResultsCyclin B synthesis continues during meta-II arrest in
CSF extracts
Unfertilized Xenopus eggs arrested at meta-II are
known to continue the synthesis of cyclin B proteins
(Thibier et al., 1997). We first examined whether cyclin B
is also synthesized in CSF extracts. When CSF extracts
were incubated in the presence of 35S-methionine and 35S-
cysteine, considerable amounts of the label were incorpo-
rated into proteins (Fig. 1A). Quantitative analysis after a
30-min labeling revealed that protein synthesis in CSFout cycloheximide were incubated in the presence of 35S-labeled methionine
antibody-beads (IP). Whole extracts after the incubation (S) and proteins
d (upper) or stained with CBB to support that equal levels of proteins were
bulk protein synthesis in CSF extracts was measured at various times after
s represent the standard deviation of three measurements. (B) The protein
The synthesis rate in I-phase extracts is taken as 1. (C) The protein synthesis
rate at the beginning of incubation is taken as 1.
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(I-phase) extracts, which mimic fertilized eggs undergoing
active protein synthesis (Fig. 1B). CSF extracts retained
more than 60% of the initial protein synthesis levels when
examined 2 h later (Fig. 1C). As seen in Fig. 1A, the
major proteins synthesized in CSF extracts were those at
45 kDa (arrowhead), which were B-type cyclins that
could be precipitated with Xenopus cyclin B antibodies.
The amount of cyclin B synthesis in CSF extracts was as
much as 52% of that in activated extracts (unpublished
data), consistent with the difference in amount of radio-
label incorporated into total proteins in the two types of
extracts. This result was surprising since in activated
extracts, newly synthesized cyclin B accumulates to an
amount sufficient to generate a metaphase level of Cdc2
activity within a 2-h incubation. Therefore, cyclin B
synthesized in CSF extracts would be expected to increase
significantly during a 2-h incubation, resulting in an
accompanying increase in Cdc2 activity. However, we
observed that both the cyclin B amount (see Fig. 3G) and
the Cdc2 activity level were unchanged in CSF extracts
during the 2-h incubation period (see Figs. 3E, F). These
observations suggested that a considerable amount of
cyclin B degradation, equal to the amount of new
synthesis, must take place during meta-II arrest in CSF
extracts.
Increase in Cdc2 activity induces rapid cyclin B
degradation in CSF extracts
If cyclin B degradation is balanced with cyclin B
synthesis in CSF extracts to maintain Cdc2 activity at a
constant level, it must be precisely regulated. To obtain aFig. 2. Cyclin B degradation is induced by elevated Cdc2 activity in CSF extract
length cyclin B1 protein is expressed as a function of time. Cyclin B1 was ad
endogenous cyclin B proteins and exogenously added cyclin B1 were examined b
cyclin B2 amount in CSF-arrested extracts incubated with various amounts of eit
negative (KN)-Cdc2 was examined by immunoblotting.clue to the regulation of cyclin B degradation during meta-
II arrest, we added various amounts of histidine-tagged
full-length Xenopus cyclin B1 (His-cyclin B1) to CSF
extracts and examined the changes in Cdc2 activity in the
extracts. As shown in Fig. 2A, when His-cyclin B1 was
first added to CSF extracts, the rapid increases in Cdc2
activity were proportional to the amount of His-cyclin B1
added. Subsequently, the Cdc2 activity dropped to the
initial levels within 50 min of His-cyclin B1-addition,
regardless of the amount of His-cyclin B1 added and the
initial level of Cdc2 activity was maintained thereafter.
Immunoblot analysis of cyclin B revealed that the rapid
decline of Cdc2 activity in the extracts was caused by
cyclin B degradation (Fig. 2B). However, the exogenously
added cyclin B was chiefly degraded while endogenous
proteins were not so much: cyclin B synthesis continued in
CSF extracts added with His-cyclin B1 but at rather lower
rates (data not shown). This result might indicate that the
exogenous cyclin B was more sensitive to degradation than
endogenous cyclin B. To test this possibility, we added
DN-cyclin B2 to CSF extracts, which can generate Cdc2
activity but is indestructible because of the lack of the
destruction box (Holloway et al., 1993), and examined the
changes in cyclin B in the extracts. Consistent with a
previous study (Minshull et al., 1994), the result showed
that in CSF extracts to which DN-cyclin B2 was added, the
degradation of endogenous cyclin B was proportional to
the amount of DN-cyclin B2 added (Fig. 2C). A similar
result was obtained with DN-cyclin B1 (data not shown).
Thus, endogenous cyclin B in CSF extracts is capable of
being degraded, but when exogenous cyclin B is added,
the exogenous cyclin B is more likely to be degraded than
endogenous one. To know whether cyclin B degradation iss. (A) Cdc2 activity in CSF extracts together with various amounts of full-
ded to CSF extracts at the beginning of incubation. (B) The amounts of
y immunoblotting with cyclin B1 and B2 antibodies. (C) The endogenous
her indestructible DN-cyclin B2 or DN-cyclin B2 in a complex with kinase
Fig. 3. APC/C–Cdc20 activity is required for cyclin B degradation induced by elevated Cdc2 activity in CSF extracts. CSF extracts were either
immunodepleted of the APC/C with a Cdc27 antibody or mock-depleted (A, left, C, E) or incubated with either a Cdc20-inhibiting antibody or a nonspecific
IgG (B, D, F). In some experiments, CSF extracts were added with an undegradable mutant of Emi1 to inhibited Cdc20 and treated with CHX to inhibit
protein synthesis (H). Samples were assayed for cyclin B degradation after Ca2+-addition by immunoblotting with a cyclin B2 antibody (A, right, B) and for
Cdc2 activity after the addition of cyclin B1 (50 nM) (C, D) or without cyclin B addition (E, F, H). CSF extracts at 120 min after incubation with either the
Cdc20-inibiting antibody or the control IgG were immunoblotted with Xenopus cyclin B1 and B2 antibodies (G). A part of the same transferred membrane
was stained with Amido Black to support that equal levels of proteins were applied (G, bottom). Similar results were obtained in two or three independent
experiments (C–F, H).
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Fig. 4. The regulation of Cdc2 activity through APC/C–Cdc20-mediated
cyclin B degradation operates in CSF-arrested eggs. (A, B) Cdc2 activity
in CSF-arrested eggs injected with cyclin B1 and/or Emi1 is expressed as a
function of time. CSF-arrested eggs were first injected with EGTA to
inhibit activation either with or without undegradable Emi1 to inhibit
Cdc20 (A, B), and then given a second injection of cyclin B1 (A). Injected
eggs were examined for Cdc2 activity at various times after cyclin B1
injection (A) or Emi1 injection (B). (C) CSF-arrested eggs at 120 min after
injection of either Emi1 or buffer (no protein) were examined for the cyclin
B amount by immunoblotting. A part of the same transferred membrane
was stained with Amido Black to support that equal levels of proteins were
applied (C, bottom). Similar results were obtained in three independent
experiments (A, B).
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amount, we added DN-cyclin B2 in complex with a kinase
negative mutant of Cdc2 (KN-Cdc2), which does not
generate Cdc2 activity when added to CSF extracts. In
CSF extracts to which the complex of DN-cyclin B2 and
KN-Cdc2 was added, the degradation of endogenous
cyclin B was not induced (Fig. 2C). These results indicate
that in CSF extracts, the elevation of Cdc2 activity causes
cyclin B degradation that continues until Cdc2 activity
returns to the meta-II level.
Cyclin B degradation under CSF arrest depends
on APC/C–Cdc20
We next examined whether APC/C–Cdc20 is involved
in the cyclin B degradation induced by elevated Cdc2
activity in CSF extracts. To do this, we ablated APC/C–
Cdc20 activity from CSF extracts by either immunodeple-
tion of the APC/C with a Cdc27 antibody or suppression
of Cdc20 with a Cdc20-inhibiting antibody. As shown in
Figs. 3A and B, either method effectively impaired cyclin
B degradation induced by Ca2+-addition to CSF extracts,
demonstrating that APC/C–Cdc20 activity was success-
fully ablated. When His-cyclin B1 was added to CSF
extracts deprived of APC/C–Cdc20 activity, Cdc2 activity
was quickly elevated but with further incubation did not
decline to the starting level, as was seen in control extracts
with normal APC/C–Cdc20 activity (Figs. 3C, D). Thus, in
CSF extracts, APC/C–Cdc20 activity is required for the
cyclin B degradation that antagonizes the elevated Cdc2
activity caused by exogenous cyclin B addition. To
confirm that APC/C–Cdc20-mediated cyclin B degradation
is also ongoing during meta-II arrest in CSF extracts
without exogenous cyclin B, we examined Cdc2 activity in
CSF extracts deprived of APC/C–Cdc20 activity. The
results showed that Cdc2 activity was gradually elevated
with the cyclin B amount being increased in such extracts
(Figs. 3E–G), indicating that during meta-II arrest, APC/
C–Cdc20-mediated degradation of cyclin B is required to
keep Cdc2 activity constant at the meta-II level in the
presence of continuous cyclin B synthesis.
It should be noted that when protein synthesis in CSF
extracts was inhibited by the addition of cycloheximide
(CHX), Cdc2 activity was gradually declined (approxi-
mately 20–30% of the meta-II level of activity in a 2-h
incubation; Fig. 3H). The decrease in Cdc2 activity induced
by CHX-addition was mostly independent of APC/C–
Cdc20 since, in CSF-extracts whose Cdc20 was inhibited
by the addition of an undegradable mutant of Emi1 (Ohsumi
et al., 2004), a similar extent of decrease in Cdc2 activity
was induced by CHX-addition (Fig. 3H). This result
suggests that a small portion of cyclin B is continuously
degraded during meta-II arrest, independently of APC/C–
Cdc20 activity. The APC/C–Cdc20-independent cyclin B
degradation is insufficient to keep Cdc2 activity from
increasing, since, in the absence of APC/C–Cdc20 activity,Cdc2 activity is increased to 160% of the meta-II level of
activity in a 2-h incubation (Figs. 3E, F, H).
Regulation of cyclin B degradation in CSF-arrested eggs
We also examined whether or not the regulation of Cdc2
activity levels by APC/C–Cdc20-mediated cyclin B degra-
dation operates in intact CSF-arrested eggs. When mature
eggs were injected with His-cyclin B1 along with EGTA,
which inhibited egg activation induced by injection, the
Cdc2 activity level was transiently elevated but settled at the
initial, meta-II level afterward (Fig. 4A). The return of
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APC/C–Cdc20, as it was prevented by inhibition of Cdc20
with the undegradable Emi1 (Fig. 4A). Immunoblot analysis
revealed that cyclin B degradation was responsible for the
decline of elevated Cdc2 activity (unpublished data).
Furthermore, Cdc2 activity gradually increased accompany-
ing the increase in the cyclin B amounts in mature eggs
whose Cdc20 was inhibited with the Emi1 mutant (Figs. 4B,
C). Thus, the feedback control of Cdc2 activity levels
through the activation of APC/C–Cdc20-mediated cyclin B
degradation operates during meta-II arrest in CSF-arrested
eggs.
Mos/MAPK activity is required to maintain Cdc2 activity at
the meta-II level
It was noteworthy that following the peak of Cdc2
activity seen after the addition of His-cyclin B1 to CSF
extracts, the Cdc2 activity level never declined below the
initial, meta-II level (Fig. 2A). This result suggested that
under CSF arrest there is a threshold of Cdc2 activity below
which cyclin B degradation is turned off, thereby maintain-
ing the meta-II arrest. To investigate whether Mos is
involved in the turning off of cyclin B degradation under
CSF arrest, we ablated Mos activity from CSF extracts using
Mos antibodies prior to the addition of His-cyclin B1. To do
this, CSF extracts were first immunodepleted of Mos (Fig.
5A) and then a neutralizing antibody against Mos wasFig. 5. Mos/MAPK activity is required for the turn off of cyclin B degradation a
immunodepleted or mock-depleted of Mos (A, upper), mixed with either a Mos-in
for the changes in cyclin B and MAPK (B, D, F) by immunoblotting and for the c
cyclin B1 (50 nM) (B, C), either GST-Ste11DN fusion protein or GST alone (D,
positions of active and inactive MAPK are indicated by arrowheads and bars,
experiments (C, E, G).added. Under our experimental conditions, both treatments
were necessary for the complete ablation of Mos activity
from CSF extracts; the ablation of Mos activity was
confirmed by the complete inactivation of MAPK in the
extracts (Fig. 5B). When His-cyclin B1 was added to Mos-
ablated extracts, both endogenous and exogenous cyclin B
proteins were degraded to undetectable amounts, accom-
panying Cdc2 inactivation to an I-phase level (Fig. 5C). In
mock-treated extracts, cyclin B persisted, with the meta-II
level of Cdc2 activity maintained (Figs. 5B, C). Thus, the
Mos/MAPK pathway is involved in the turning off of cyclin
B degradation once the meta-II level of Cdc2 activity is
restored.
We found that in the Mos-ablated extracts, nuclear
formation occurred after Cdc2 inactivation (data not
shown). The result presented in Fig. 5C, therefore,
suggested that the Mos-dependent suppression of cyclin B
degradation is required to maintain meta-II arrest. Support-
ing this notion, when Mos was ablated from CSF extracts,
endogenous cyclin B was degraded to an undetectable
amount, without a requirement for exogenous His-cyclin B.
Correspondingly, Cdc2 activity decreased to an I-phase
level (Figs. 5D, E) and nuclear formation occurred in the
extracts with inactivated Cdc2 (data not shown). The meta-
II level of cyclin B and Cdc2 activity was restored by the
addition of Ste11DN, a constitutive active form of a yeast
MAPKK kinase (Gotoh et al., 1994). When MAPK activity
was partially restored by the addition of smaller amounts oft the metaphase level of Cdc2 activity in CSF extracts. CSF extracts were
hibiting antibody (Mos-dep) or nonspecific IgG (mock-dep) and examined
hanges in Cdc2 activity (C, E, G). Samples were taken after the addition of
E), and either a Cdc20-inhibiting antibody or nonspecific IgG (F, G). The
respectively. Similar results were obtained in two or three independent
Fig. 6. Mos/MAPK activity is required for suppressing APC/C–Cdc20-
mediated cyclin B degradation in MII at lower than the metaphase level of
Cdc2 activity. Meiotic cycling extracts were incubated with DMSO, U0126
or U0126 in combination with either GST-Ste11DN (A, B), a Cdc20-
inhibiting antibody (a-Cdc20) or nonspecific IgG (cont. Ig) (C, D).
Samples were examined for the changes in cyclin B2 and MAPK by
immunoblotting (A, C) and Cdc2 activity (B, D) by histone H1 kinase
assays. The Cdc20-inhibiting antibody and nonspecific IgG were added to
extracts at the indicated time (arrowhead in panel D). The positions of
active and inactive MAPK are indicated by arrowheads and bars,
respectively. Similar results were obtained in two independent experiments
(B, D).
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was similarly restored (data not shown). Thus, the turning
off of cyclin B degradation at the meta-II level of Cdc2
activity is dependent on Mos/MAPK activity and a partial
activation of MAPK is sufficient for this regulation. To
examine whether APC/C–Cdc20 activity is required for
cyclin B degradation induced by Mos-ablation, we added
the Cdc20-inhibiting antibody to CSF extracts that had been
deprived of Mos activity. As seen in Fig. 5G, when APC/C–
Cdc20 was suppressed with the Cdc20-inhibiting antibody
in the absence of Mos activity, cyclin B persisted and Cdc2
activity was maintained at the meta-II level (Figs. 5F, G).
These results indicate that Mos/MAPK activity is required
to turn off APC/C–Cdc20-mediated cyclin B degradation at
the meta-II level of Cdc2 activity, supporting the notion that
Mos is essential for the maintenance of CSF arrest.
Mos/MAPK activity is required to suppress precocious
cyclin B degradation in MII
Although Mos/MAPK activity is essential for establish-
ing meta-II arrest, its role in the process of CSF establish-
ment in MII is not clear. To investigate this, we utilized the
meiotic cycling extract prepared from metaphase I (meta-I)
oocytes, which performs the meiotic progression from meta-I
to meta-II (Iwabuchi et al., 2000). In the meiotic extract,
Cdc2 activity is high at the beginning, corresponding to the
meta-I state, gradually declines with incubation time, but
subsequently increases. After reaching the meta-II level, the
high level of Cdc2 activity is maintained, corresponding to
meta-II arrest. This change in Cdc2 activity occurs in parallel
with the changes in the cyclin B amounts owing to the
absence of inhibitory phosphorylation of Cdc2 during the
MI–MII transition period (Iwabuchi et al., 2000, see also Fig.
6). To examine the role of Mos/MAPK activity in the
establishment of meta-II arrest, we added U0126, an
inhibitor of MEK, to meiotic extracts. Immunoblot analysis
revealed that in U0126-treated meiotic extracts, MAPK was
gradually inactivated, accompanied by a decline in Cdc2
activity, and remained completely inactive afterwards (Fig.
6A). In the absence of MAPK activity, the decline in Cdc2
activity was initially reversed but soon after declined again,
instead of continuing to increase until the meta-II level was
reached (Fig. 6B). By the addition of Ste11DN to U0126-
treated meiotic extracts, a small fraction of MAPK remained
activated, and Cdc2 activity was elevated to the meta-II level
(Figs. 6A, B). Immunoblot analysis confirmed that the
precocious decline of Cdc2 activity in the absence of MAPK
activity was caused by a decrease in the amount of cyclin B.
When APC/C–Cdc20 was suppressed with the Cdc20-
inhibiting antibody, Cdc2 activity was elevated to a high
level in the absence of Mos/MAPK activity (Figs. 6C, D).
Thus, in the MAPK-ablated meiotic extracts, the precocious
decline of Cdc2 activity was caused by APC/C–Cdc20-
mediated cyclin B degradation. These results strongly
suggest the role of Mos/MAPK activity in the establishment
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cyclin B degradation is prevented during the CSF arrest.Discussion
In this study, we have investigated the regulatory
mechanism for the Cdc2 activity level in CSF-arrested eggs
and extracts. Our results have demonstrated that under CSF
arrest, Cdc2 activity is kept constant at the meta-II level as
follows; (i) cyclin B is continuously synthesized and, cor-
respondingly, the Cdc2 activity level is elevated, (ii) when the
Cdc2 activity level is elevated above the meta-II level, cyclin
B degradation dependent on APC/C–Cdc20 is activated and
the initial meta-II level of Cdc2 activity level is restored, and
(iii) when Cdc2 activity is decreased to the meta-II level,
cyclin B degradation is suppressed, depending on Mos/
MAPK activity (Fig. 7). Thus, under CSF arrest, Cdc2 acti-
vity is maintained at the meta-II level through the dynamic
feedback control based on APC/C–Cdc20-mediated cyclin B
degradation (red arrows in Fig. 7), rather than by cessation of
cyclin B metabolism or a coincidental equilibrium between
the synthesis and degradation rates of cyclin B.
Regulation of cyclin B degradation under CSF arrest
The notion has been accepted that cyclin B degradation is
suppressed through inhibition of APC/C–Cdc20 under CSF
arrest (for review, see Tunquist and Maller, 2003). Our data
have shown, however, that cyclin B degradation mediated
by APC/C–Cdc20 occurs and even is required to keep theFig. 7. Model for the regulation of cyclin B degradation under CSF arrest. Cyclin B
open arrow). APC/C–Cdc20-mediated cyclin B degradation is suppressed by a M
level, but activated through hyperphosphorylation of APC/C components when C
Cdc2 activity to meta-II levels (downward open arrow). Cdc2 activity is thus maint
mediated cyclin B degradation (red arrows). See text for details.Cdc2 activity level constant in CSF-arrested eggs and
extracts. This evokes the question of how APC/C–Cdc20-
mediated cyclin B degradation is activated under CSF arrest.
Our results indicate that cyclin B degradation is activated
when Cdc2 activity is elevated beyond the meta-II level, and
depends upon both the APC/C and Cdc20 (Figs. 2–4).
Similar activation of cyclin B degradation is also induced
when CSF extracts are treated with microcystin (Lorca et al.,
1991) or okadaic acid (Lorca et al., 1998), potent inhibitors
of protein phosphatase 2A; this phosphatase is thought to
catalyze protein dephosphorylation that antagonizes protein
phosphorylation by Cdc2. The cyclin B degradation induced
by okadaic acid-treatment is also dependent on APC/C–
Cdc20 (Lorca et al., 1998). Thus, it is very likely that the
under CSF arrest, cyclin B degradation is activated in the
presence of high Cdc2 activity, probably through the
enhanced phosphorylation of protein substrates; this phos-
phorylation is distinct from that induced by CaMKII
activity, which activates cyclin B degradation that induces
exit from MII (Lorca et al., 1993). It is noteworthy in this
context that separase, a protease responsible for sister
chromatid separation, is inhibited by specific phosphoryla-
tion induced by Cdc2 activity higher than the meta-II level
(Stemmann et al., 2001).
The most likely targets for high Cdc2 activity are APC/C
components, particularly Apc1, Cdc27 and Cdc16, which
are massively phosphorylated in M-phase (Kraft et al.,
2003). We have confirmed that Cdc27 is hyperphosphory-
lated in CSF extracts with Cdc2 activity higher than the
meta-II level. The APC/C is known to be activated by
phosphorylation in M-phase, and recent studies havesynthesis continues under CSF arrest and Cdc2 activity is elevated (upward
os/MAPK-dependent activity when Cdc2 activity is lower than the meta-II
dc2 activity is elevated beyond the meta-II level, resulting in a decline in
ained at the meta-II level through the dynamic regulation for APC/C–Cdc20-
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possesses activity to catalyze polyubiquitination of cyclin B
(Vorlaufer and Peters, 1998) and to bind its destruction box
(Yamano et al., 2004). Thus, it appears that under CSF
arrest, the APC/C is in the active state but is prevented from
catalyzing cyclin B ubiquitination by Mos/MAPK activity
when Cdc2 activity is lower than the meta-II level. This
putative effect of Mos/MAPK is thought to be ineffective
for the APC/C whose components are hyperphosphorylated
since, in the presence of Cdc2 activity higher than the meta-
II level, the APC/C effectively mediated cyclin B degrada-
tion, by a Cdc20-dependent mechanism (Figs. 3 and 4). Our
data do not exclude the possibility that high Cdc2 activity
antagonizes the suppression of the APC/C by Mos/MAPK
activity.
It has been reported that Cdc20 is inhibited by Emi1 in
MII, and that this inhibition is responsible, at least in part,
for CSF arrest (Reimann and Jackson, 2002). However,
according to our analysis, Emi1 is not present in CSF-
arrested eggs, and arrest caused by Emi1 is distinct from
CSF arrest in both dependency on MAPK activity and
sensitivity to Ca2+-induced activation (Ohsumi et al., 2004).
Thus, the regulation of Cdc20 under CSF arrest is not clear,
although our results clearly show that its activity is essential
for cyclin B degradation under CSF arrest.
Taken together, our results lead us to the following
model. We propose that under CSF arrest, cyclin B
degradation is suppressed through inhibition of the APC/C
by a mechanism that depends on Mos/MAPK activity,
whenever Cdc2 activity decreases below the meta-II level.
However, this suppression is ineffective for the APC/C
whose components are hyperphosphorylated in the presence
of Cdc2 activity higher than the meta-II level (Fig. 7).
The role of the Mos/MAPK pathway in CSF arrest
Although there is a consensus that Mos/MAPK activity is
essential for the establishment of CSF arrest, there are
contradictory arguments regarding whether or not Mos/
MAPK activity is required for the maintenance of CSF
arrest (Tunquist and Maller, 2003). Our results favor the
positive role of Mos/MAPK activity in the maintenance of
CSF arrest, and are consistent with previous studies
showing that inhibition of Mos or MAPK with a neutraliz-
ing antibody and addition of Mkp1, a MAPK-inactivating
phosphatase, causes release from CSF arrest in unfertilized
eggs or CSF-arrested extracts (Furuno et al., 1997; Minshull
et al., 1994). On the contrary, others have reported that
inhibition of MAPK with U0126 does not cause release
from CSF arrest (Reimann and Jackson, 2002; Tunquist et
al., 2002). In our unpublished experiments, however,
U0126-treatment of CSF extracts failed to completely
inactivate MAPK, even at the highest concentration used
(500 AM) (Yamamoto, unpublished). The small fraction of
MAPK remaining active, which was likely to be missed in
detection by immunoblotting with anti-phospho-MAPKantibodies, is significant since even partial activation of
MAPK in meiotic extracts was sufficient to suppress
precocious cyclin B degradation in MII (Fig. 5). The
requirement of Mos/MAPK activity for the maintenance
of CSF arrest has also been challenged by studies showing
that CSF arrest is maintained when extracts are immunode-
pleted of Rsk or Bub1, downstream components of the
MAPK pathway, which are known to be involved in the
establishment of CSF arrest (Bhatt and Ferrell, 1999;
Tunquist et al., 2002). However, the downstream component
of Mos/MAPK that is depleted should be taken into account,
since it has been suggested that there is an alternative
pathway other than the one leading to activation of Rsk that
possibly contributes to the maintenance of M-phase arrest
(Horne and Guadagno, 2003; Lefebvre et al., 2002).
Although the reasons for the discrepancies discussed above
are not clear, we emphasize that when Mos activity is
ablated from CSF-arrested eggs and extracts, CSF arrest is
not maintained (Furuno et al., 1997).
In good agreement with a precocious decline of Cdc2
activity in MII in Mos-ablated maturing oocytes (Dupre et
al., 2002), our data showed that in the absence of Mos/
MAPK activity APC/C–Cdc20-mediated cyclin B degrada-
tion was activated at a Cdc2 activity level much lower than
the meta-II level (Fig. 6). Therefore, the failure of CSF
arrest in both Mos-ablated oocytes and MAPK-inhibited
meiotic extracts is ascribable to the precocious activation of
APC/C–Cdc20-mediated cyclin B degradation by the low
level of Cdc2 activity. According to our results, the Mos/
MAPK pathway plays a consistent role in both establish-
ment and maintenance of CSF arrest; namely, it prevents
APC/C–Cdc20-mediated cyclin B degradation when Cdc2
activity is lower than the meta-II level. More importantly,
the dynamics of Cdc2 activity during MII is well explained
by this regulation of cyclin B degradation in the presence of
continuous cyclin B synthesis. We, therefore, propose that
the Mos/MAPK pathway plays an essential role in both
establishment and maintenance of CSF-arrest through
prevention of polyubiquitination of cyclin B by APC/C–
Cdc20 when Cdc2 activity is lower than the meta-II level.
The mechanism involved in the prevention of APC/C–
Cdc20 remains to be elucidated.
In summary, we have demonstrated that under CSF
arrest, Cdc2 activity is kept constant at the meta-II level
through the precise turning on and off of APC/C–Cdc20-
mediated cyclin B degradation in response to the Cdc2
activity level. The present finding that APC/C–Cdc20 does
mediate cyclin B degradation under CSF arrest provides a
novel view of the regulatory mechanism for CSF arrest in
unfertilized eggs of vertebrates.Acknowledgments
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